RSPO3 and colorectal carcinoma: Our experiments provide the rationale for a broad utility of Rspo3 antagonism for the treatment of CRC that would include not only tumors with PTPRK-RSPO3 fusions, but also tumors with common Wnt pathway-activating mutations.